Evaluation of standardized cannabidiol extracts in the treatment of inflammatory bowel disease

This project is to test the potential of standard extracts of Hemp cannabis plants from 50N Biotech, a Canada–based biotech company, in the treatment of inflammatory bowel disease (IBD). Our working hypothesis is that these extracts strongly suppress the inflammation in the gut of individuals who have the disease, and the combination treatment of these extracts with clinical-use drugs will result in improvement in the management of the IBD. We will use preclinical models to test our hypothesis. The primary outcome measures of the treatments will include the severity of the colitis – a IBD-like disease. We will compare the outcomes of the cannabis extract monotherapy with that of their combination therapy with aminosalicylic acids (a clinical-use drug for IBD) in the treatment of colitis.

Faculty Supervisor:

Caigan Du

Student:

Partner:

50N Biotech

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

The University of British Columbia

Program: